BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 19070804)

  • 1. [Metastases from urothelial carcinoma : future and prospects].
    Lebret T; Méjean A
    Prog Urol; 2008 Nov; 18 Suppl 7():S277-84. PubMed ID: 19070804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous metastases from transitional cell carcinoma of the bladder.
    Block CA; Dahmoush L; Konety BR
    Urology; 2006 Apr; 67(4):846.e15-7. PubMed ID: 16600346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rare locations of metastases from urothelial carcinoma].
    Lebret T; Méjean A
    Prog Urol; 2008 Nov; 18 Suppl 7():S289-97. PubMed ID: 19070806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-grade urothelial carcinoma of the urinary bladder showing acquisition of microcystic histology in the penile metastasis: histogenetic considerations.
    Barresi V; Ieni A; Magno C; Barresi G
    Pathol Res Pract; 2009; 205(8):568-71. PubMed ID: 19179016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous metastases: an ominous sign of urothelial carcinoma of the bladder.
    de Giorgi V; Sestini S; Massi D; Panelos J; Grazzini M; Lotti T
    Dermatol Surg; 2008 Nov; 34(11):1574-6. PubMed ID: 18798746
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful treatment of metastatic skin lesions with electrochemotherapy.
    Kubota Y; Mir LM; Nakada T; Sasagawa I; Suzuki H; Aoyama N
    J Urol; 1998 Oct; 160(4):1426. PubMed ID: 9751373
    [No Abstract]   [Full Text] [Related]  

  • 7. Metastatic umbilical mass from transitional cell carcinoma of the bladder.
    Spiess PE; Kassouf W; Tukaram K; Roy I
    Can J Urol; 2005 Oct; 12(5):2856-8. PubMed ID: 16274525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of metastatic transitional cell carcinoma in response to tamoxifen.
    Dellagrammaticas D; Bryden AA; Collins GN
    J Urol; 2001 May; 165(5):1631. PubMed ID: 11342939
    [No Abstract]   [Full Text] [Related]  

  • 9. Current status of targeted therapy in metastatic transitional cell carcinoma of the bladder.
    Sadeghi S; Garcia JA
    Semin Oncol; 2012 Oct; 39(5):608-14. PubMed ID: 23040257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of everolimus in metastatic urothelial cancer.
    Smith AB; Pruthi RS
    BJU Int; 2013 Aug; 112(4):427-8. PubMed ID: 23879903
    [No Abstract]   [Full Text] [Related]  

  • 11. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.
    Cho KS; Seo HK; Joung JY; Park WS; Ro JY; Han KS; Chung J; Lee KH
    J Urol; 2009 Dec; 182(6):2625-30. PubMed ID: 19836779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Metastastic urothelial carcinoma: is there a role for surgery?].
    Lebret T; Méjean A
    Prog Urol; 2008 Nov; 18 Suppl 7():S285-8. PubMed ID: 19070805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin metastasis of 'nested type' of urothelial carcinoma of the urinary bladder.
    Zwenzner EM; Kaatz M; Ziemer M
    J Cutan Pathol; 2006 Nov; 33(11):754-5. PubMed ID: 17083696
    [No Abstract]   [Full Text] [Related]  

  • 14. [Anti-ErbB targeted therapy and urothelial tumors].
    Amsellem-Ouazana D; Goldwasser F; Bieche I; Lidereau R; Zerbib M
    Prog Urol; 2005 Dec; 15(6 Suppl 1):1229-35. PubMed ID: 16734210
    [No Abstract]   [Full Text] [Related]  

  • 15. Urothelial carcinoma with abundant myxoid stroma.
    Tavora F; Epstein JI
    Hum Pathol; 2009 Oct; 40(10):1391-8. PubMed ID: 19535127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment?
    Scosyrev E; Yao J; Messing E
    Urology; 2009 Apr; 73(4):822-7. PubMed ID: 19193403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics.
    Shanks JH; Iczkowski KA
    Histopathology; 2009 Jun; 54(7):885-900. PubMed ID: 19178589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments.
    Sun B; Moibi JA; Mak A; Xiao Z; Roa W; Moore RB
    J Urol; 2009 Mar; 181(3):1361-71. PubMed ID: 19157446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid clinical deterioration and leukemoid reaction after treatment of urothelial carcinoma of the bladder: possible effect of granulocyte colony-stimulating factor.
    Perez FA; Fligner CL; Yu EY
    J Clin Oncol; 2009 Dec; 27(34):e215-7. PubMed ID: 19786665
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer.
    Boudreaux KJ; Clark PE; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Chang SS
    J Urol; 2009 Feb; 181(2):540-5; discussion 546. PubMed ID: 19084855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.